At last, mHealth is more widely recognized for its role in bridging big communications and data gaps across clinical research. From mobile apps to support study patients with tailored communications materials to wearable devices collecting much-needed data in real-time—mHealth has moved from hot trend to real world.
Early adopters paved the way for the rest of us, and as we enter this next phase of innovation, we do so with a better understanding about what works and what doesn’t. Recognizing the impact mHealth has on clinical research today, how do we advance adoption in the years ahead? What considerations must be made before deployment, and what makes a program leveraging mHealth a successful one? How can we continue to pursue new options for clinical study communities to enhance the trial process?
In considering new technologies to help engage study communities, we must not forget about the foundation upon which everything is built: awareness. When it comes to mHealth, we know that studies with strong communication plans garner the best results—from patient engagement to medication compliance. But innovation doesn’t mean out with the old and in with the new. In fact, to succeed we must blend traditional methods with modern approaches; offering the patient or physician the right to choose their method of participation is the innovation.
To optimize investment in these new technologies, we must move from investing in tactics on a study-by-study basis and consider rolling out approved, best-of-breed technologies across multiple studies to reduce costs and streamline processes. This also allows sponsors to re-direct more of their budget to the foundation of awareness—awareness of clinical trial opportunities, awareness of tools available to the study community to stay engaged, etc.
mHealth bridges the engagement gap and gives sponsors the ability to communicate with patients and sites on a better level, but only if we under-stand how to leverage them fully.
Written by Guest Writer Aaron Fleishman. Fleishman focuses on Marketing Expansion and Innovation at BBK Worldwide. Fleishman helps pharmaceutical sponsors, advocacy organizations and patient thought-leaders create and deploy award-winning, innovative strategies that generate awareness and engagement surrounding clinical research. A well-regarded speaker and forward-thinking strategist, Aaron was named to the PharmaVOICE 100 in 2014 for his commitment to patients, study engagement and technology innovation.
This article was reprinted from Volume 23, Issue 10, of The CenterWatch Monthly, an industry leading publication providing hard-hitting, authoritative business and financial coverage of the clinical research space. The Action Items section features short columns focusing on actionable or how-to advice from clinical trial professionals. To submit an Action Item, please contact firstname.lastname@example.org. Subscribe >>